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Abstract: Rhabdomyolysis is a clinical and laboratory syndrome that is caused by various 
etiologies, involving the skeletal muscle. Clarithromycin, like other macrolides, is an inhibitor 
of CYP450 3A4, the major enzyme responsible for the metabolism of several drugs, in 
  particular some statins. Rhabdomyolysis related to macrolide–statin interaction has previously 
been described. To date, rhabdomyolysis induced by clarithromycin has been described in 
only one previous report. We describe the case of a 90-year-old Caucasian male, admitted to 
the University Hospital of Pisa for dyspnea, who developed rhabdomyolysis associated with 
clarithromycin administration.
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Introduction
Adverse drug reactions (ADRs), including interactions, in older people are a common 
cause of admission to hospital1 and are also a common cause of disease in hospitalized 
patients. Frail elderly patients appear to be particularly at risk of ADRs. In some 
cases, this is because insufficient account is taken of the effect of age and frailty 
on the pharmacokinetic and pharmacodynamic of the drug, especially in relation to 
hepatic2 and renal elimination.3 Although many ADRs are recognized during the drug 
development process and before licensing, this is not always the case, especially when 
they are uncommon or rare.3 Moreover, patients with severe cognitive impairment 
may not be able to refer symptoms related to an ADR, making the recognition of this 
clinical condition a medical problem.4
Rhabdomyolysis is a clinical and laboratory syndrome that is caused by various 
etiologies, involving the skeletal muscle.5 Rhabdomyolysis is characterized by 
the leaking of myoglobin and other intracellular proteins and electrolytes into the 
circulation, and may be associated with a wide variety of diseases, injuries, medications, 
and toxins.5 It is important to recognize drug-induced rhabdomyolysis because 
clinical effects are usually reversible.4 Rhabdomyolysis related to macrolide-statin 
interaction has previously been described.6–8 Clarithromycin, like other macrolides, 
is an inhibitor of CYP450 3A4, the major enzyme responsible for the metabolism of 
several drugs, in particular some statins like simvastatin and atorvastain.6–9 To date, 
rhabdomyolysis related to clarithromycin has been reported in only one previous 
case report.10 We report the case of a 90-year-old Caucasian male, admitted to the 
University Hospital of Pisa for dyspnea, who experienced rhabdomyolysis related 
to clarithromycin treatment.
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Case report
A 90-year-old Caucasian male was admitted to the University 
Hospital of Pisa for dyspnea. He had experienced dyspnea 
for 2 weeks, and showed signs of pneumonia after a 
chest X-ray was performed. The patient was affected by 
Alzheimer’s disease, in advanced phase, and did not take 
any home-medication as referred by his general physician. 
At admission in the emergency room, clinical workup 
revealed mental confusion (the relatives referred progressive 
cognitive impairment for several months), sinus tachycardia 
(115 beats per minute), basilar wheezes, and rhonchi. Body 
temperature was 36.6°C with normal systemic blood pressure 
(140/80 mmHg), diuresis, and blood oxygen saturation 
(SO2% 96.2%). Routine laboratory exams, including 
complete blood cell count, thyroid hormones, liver (aspartate 
aminotransferase and alanine aminotransferase) and muscle 
(creatine kinase [CK]) enzymes, as well as the coagulation 
pattern, resulted within normal limits. Serum brain natriuretic 
peptide was measured and a cardiac markers’ curve 
(including myoglobin) was also started, ruling out cardiogenic 
dyspnea. Blood potassium and creatinine concentrations were 
4.96 mEq/L (reference range 3.5–5 mEq/L) and 122.8 µmol/L 
(reference range 45–90 µmol/L), respectively.
At the emergency room, a diagnosis of acquired pneumonia 
was made and treatment with ceftriaxone (1 g four times daily, 
intravenous), hydration (crystalloid 1.5 L/day), aerosol with 
salbutamol and oxitropium, O2 inhalation (3 L/minute), and 
dalteparin (2500 UI, subcutaneous) was started. After the 
geriatric ward admission, clarithromycin (500 mg two times 
daily, intravenous) was also started. On the second day of 
hospitalization, for continuing sinus tachycardia, in the absence 
of any evident causes (fever, hypotension, arterial-venous 
fistula, thyrotoxicosis, suspected drug treatments, etc) beta-
blocker treatment (bisoprolol 1.25 mg, daily) was added and 
a cardiac markers’ curve was restarted (Figure 1). The second 
point of the curve, almost 6 hours after the third clarithromycin 
dose, revealed a huge myoglobin increase (1144 ng/mL; 
8.5 times the upper normal range [28–138 ng/mL]) without 
electrocardiogram modifications. Serum CK was then 
measured, resulting markedly elevated (1100 U/L; 6.5 
times the upper normal range [38–180 U/L]) along with 
a mild creatinine increase (152.9 µmol/L), in the absence 
of liver enzyme alterations (aspartate aminotransferase, 
alanine aminotransferase). Urine color concomitantly 
changed toward dark brown and hemogasanalysis revealed 
a slight respiratory insufficiency type 1 with normal pH. A 
diagnosis of rhabdomyolysis was made and clarithromycin 
was stopped, while the concomitant therapy with ceftriaxone, 
bisoprolol, and aerosol with salbutamol and oxitropium 
was continued. The patient was immediately treated with 
intravenous crystalloid hypotonic solution (80 mL/hour) and 
corticosteroid (40 mg methylprednisolone, intravenous). 
Serum CK and myoglobin levels decreased within a few 
days and a chest X-ray showed significant improvement. 
The patient was discharged home on the sixth hospital day 
(Figure 1) with the diagnosis of iatrogenic rhabdomyolysis 
and acquired pneumonia of unknown etiology. Indeed, serum 
and urinary antigen and antibody exams excluded the presence 
of Legionella pneumophila, Streptococcus pneumoniae, and 
Mycoplasma pneumoniae while virus infection assessments 
were not performed.
Discussion
Clarithromycin, like other macrolides, is an inhibitor 
of CYP450 3A4, the major enzyme responsible for the 
metabolism of several drugs, in particular some statins as 
simvastatin and atorvastatin.3,6–9 Rhabdomyolysis related 
to macrolide and statins interaction has previously been 
described; however, rhabdomyolysis related to clarithromy-
cin has been reported in only one previous case report.8,10 In 
our case, there was an evident temporal sequence between 
clarithromycin exposure-withdrawal and the onset-recovery 
from rhabdomyolysis biochemical signs, while other potential 
causes of muscle damage were reasonably excluded. Accord-
ingly, the Naranjo probability scale confirmed a probable 
relationship (score 6/9).13
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Figure 1 Patient blood creatine kinase (CK) and myoglobin levels from emergency 
room (ER) to recovery from rhabdomyolysis.
Notes: The first four points of blood myoglobin level were obtained as part of 
two cardiac marker curves, while the following for rhabdomyolysis monitoring. 
The basal two points of blood CK value were obtained as routine analysis at ER 
and on the first day of hospitalization. The following CK values were measured for 
rhabdomyolysis monitoring after the unexpected myoglobin increase (see text for 
detail). Dotted part of the CK line represents the lacking CK values.
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A general physician and a nurse followed the patient at 
home, thus we are confident the home care was carried out 
in a correct manner, ruling out mistakes and accidental drug 
intake. Moreover, an interaction with other concomitant 
medications was improbable considering the rapid resolution 
after clarithromycin withdrawal and the elimination 
pathways of the concomitant drugs (both bisoprolol and 
ceftriaxone have hepatic and renal elimination routes).11,12 In 
addition, bisoprolol was administered at the minimal dose 
(1.25 mg) and both bisoprolol and ceftriaxone, as single 
therapy, were never related to an adverse drug reaction like 
rhabdomyolysis.
We ruled out infection as the possible cause of muscle 
damage considering the sequence of the events. In fact, the 
patient was admitted to the hospital for dyspnea developed 
at home since 2 weeks, while serum CK suddenly increased 
2 days after hospital admission. If rhabdomyolysis had 
been caused by the infection we would have expected that 
serum CK increased earlier, thus being already evident 
at hospital admission. Moreover, the most common 
rhabdomyolysis-associated bacterial infections were ruled 
out by specific tests.
The diagnosis of rhabdomyolysis, unless there is a high 
index of suspicion, can be missed since muscular pain, 
swelling, and tenderness may not be prominent or even 
absent. The definitive diagnosis should be made by laboratory 
tests including serum CK and urine myoglobin.5 In our case, 
the patient had advanced cognitive impairment making him 
unable to easily refer any symptom, and the diagnosis was 
made by the huge elevation of biochemical markers (6.5 times 
the upper normal value for CK, 8.5 times for myoglobin). 
Overall, these findings allowed us to make the diagnosis 
of rhabdomyolysis with sufficient warranty. Although 
clarithromycin associated rhabdomyolysis is mainly due to 
pharmacokinetic interactions, a direct muscle toxicity might 
be postuled.5,10
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